Advertisement

Where to find the pick of the bunch in biotech stocks

Professional investor Ailsa Craig picks three biotech stocks generating revenues and profits, and which have long-term patent protection.

Each week, a professional investor tells us where she'd put her money. This week: Ailsa Craig of the International Biotechnology Trust chooses three promising small caps.

Biotechnology remains an exciting sector, but investors need to be far more discriminating now than they were a few years ago. Growth at the largest firms has slowed, as popular products have reached their peak sales potential. There is now more scope for long-term earnings growth in smaller and medium-sized companies.

Advertisement - Article continues below

However, many of the smaller firms carry greater risk than their larger counterparts. They often do not have wellestablished portfolios of existing drugs and future earnings depend on the launch of new products. Also, drug development is a challenging, long-term business with no guarantees of success.

To avoid undue risk, investors should select companies with products that generate revenues and profits, and also have long-term patent protection. Here are three stocks that match this profile.

Turbulent but promising

Incyte (Nasdaq: INCY) has had a turbulent 18 months. It was developing a new type of cancer therapy an IDO-inhibitor', which works by stopping cancer cells from hijacking the IDO protein, which can suppress the immune system.

There were high hopes for the treatment, but a final study in April revealed the treatment regime was ineffective. As a result, the share price fell sharply and the stock is now trading at less than half the value it reached at its peak.

Advertisement - Article continues below
Advertisement
Advertisement - Article continues below

Despite the failure of the IDO-inhibitor, all is not lost. Incyte's multi-billion-dollar drug, Jakafi, is used to treat patients with a rare form of blood cancer for whom existing treatments are ineffective. Jakafi has recently received approval for a second indication in other words, it could be used for another disease and strong growth is expected to continue.

The company also has a lucrative agreement with Eli Lilly for another recently-approved product, Baricitinib, which is expected to generate additional revenues in the medium-term.

A cystic-fibrosis specialist

Vertex (Nasdaq: VRTX) has a significant market cap, but it does not have the structural problems of other large biotech companies. The company specialises in the treatment of cystic fibrosis; its product, Kalydeco, works by modifying the disease, and is very effective.

As cystic fibrosis only affects a relatively small number of patients, the company has received orphan drug' status for Kalydeco. This permits the company to charge a high price for the drug and the compound is protected from competitors. In addition, Vertex owns the drug outright so it is not sharing profits with a larger partner. Earnings-per-share are set to double over the next three years.

Attacking early-stage cancer

Genmab (Copenhagen: GEN) currently has two drugs on the market, one of which is Darzalex. The main growth-driver, this compound is a monoclonal antibody used to treat multiple myeloma, a rare form of cancer.

Darzalex is now approved for use in patients with earlier stages of the disease, which should give Genmab's revenues a considerable boost. The company is also developing a formulation of the drug that is easier to administer, which will cut infusion time substantially. This will lead to increased patient numbers and improve their quality of life.

Advertisement
Advertisement

Recommended

Visit/investments/stocks-and-shares/share-tips/600641/share-tips-of-the-week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Jan 2020
Visit/519913/share-tips-8-stocks-for-robust-returns
Share tips

Share tips: eight stocks that should deliver robust returns

Ryan Ermey of US publication Kiplinger’s Personal Finance chooses his favourite stocks for the next decade, which should be able to grow for years.
28 Dec 2019
Visit/519724/share-tips-of-the-week-166
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 Dec 2019
Visit/519436/share-tips-of-the-week-165
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Dec 2019

Most Popular

Visit/investments/commodities/gold/601444/these-seven-charts-show-exactly-why-you-must-own-gold-today
Gold

These seven charts show exactly why you must own gold today

Covid-19 is accelerating many trends that were already in existence. The rising gold price is one such trend. These seven charts, says Dominic Frisby,…
3 Jun 2020
Visit/economy/eu-economy/601463/why-a-stronger-euro-is-good-news-for-investors
EU Economy

Why a stronger euro is good news for investors

The fragile state of the eurozone has for a long time brought the threat of deflation. But the ECB’s latest moves have dampened those fears. John Step…
5 Jun 2020
Visit/investments/stockmarkets/601460/disease-rioting-and-mass-unemployment-so-why-are-markets-soaring
Stockmarkets

Disease, rioting and mass unemployment – so why are markets soaring?

Despite some pretty strong headwinds in the last year, America’s S&P 500 stock index is close to all-time highs. John Stepek explains why markets seem…
4 Jun 2020